Janux Therapeutics, Inc. annual report, FY2023

Janux Therapeutics, Inc. — FY2023 Form 10-K

Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 8, 2024. Clinical updates announced in February 2024 and an equity offering completed in March 2024 are subsequent events, not FY2023 results.

Business context

Janux is a clinical-stage biotechnology company developing tumor-activated cancer immunotherapies through its TRACTr T-cell engager and TRACIr immunomodulator platforms. Its lead candidates, JANX007 (PSMA) and JANX008 (EGFR), were in Phase 1 trials. Other pipeline programs remained preclinical or in discovery. The company had no product-sales revenue or approved products.

Financial performance and position

Metric	FY2023	FY2022
Collaboration revenue	$8.1 million	$8.6 million
Research and development expense	$54.9 million	$53.4 million
General and administrative expense	$26.1 million	$22.3 million
Operating loss	$73.0 million	$67.1 million
Interest income	$14.7 million	$4.0 million
Net loss	$58.3 million	$63.1 million
Net loss per share, basic and diluted	$1.32	$1.52
Cash used in operating activities	$50.6 million	$42.9 million

• Revenue was entirely from the Merck collaboration; Janux reports that all revenue in both years came from one customer. No product gross margin is reported because there were no product sales.
• At December 31, 2023, cash and cash equivalents were $19.2 million and short-term investments were $324.8 million; restricted cash was $0.8 million. Cash, cash equivalents and short-term investments totaled $344.0 million, excluding restricted cash.
• Current assets were $349.2 million and current liabilities $13.0 million. Total liabilities were $36.1 million, including $24.5 million of operating lease liabilities; the filing reports no debt financing balance.
• FY2023 operating expenses rose $5.4 million. Higher R&D spending on JANX007 and indirect costs, and higher G&A, were partly offset by lower JANX008 and preclinical direct costs. Net loss narrowed as interest income increased, despite a larger operating loss.
• Net cash used in investing activities was $41.2 million, mainly reflecting net purchases of short-term investments. Financing activities provided $59.5 million, primarily from a July 2023 equity and pre-funded warrant offering that generated $56.5 million net.

Clinical progress and material developments

• JANX007: In the Phase 1a dose-escalation trial, 23 subjects had been treated as of February 12, 2024; subjects were heavily pretreated. At starting doses of at least 0.1 mg, 14 of 18 subjects had PSA declines of at least 30% and 10 of 18 had declines of at least 50%. At starting step doses of at least 0.2 mg, the corresponding results were 6 of 6 and 5 of 6. CRS was reported as temporary and Grade 1 or 2; no Grade 4 or 5 treatment-related events were reported. These are interim, early-stage results, not evidence of approval or definitive efficacy.
• JANX008: Eleven heavily pretreated subjects had been enrolled across four tumor types as of February 12, 2024. The company reported one confirmed partial response in an NSCLC subject, maintained through the week-18 scan, and a 12% reduction in a large RCC mass in another subject. Two subjects had Grade 1 CRS; no Grade 2 or higher CRS, treatment-related serious adverse events or dose-limiting toxicities had been observed at that cutoff. Data are preliminary and based on a small cohort.
• Janux’s platform is designed to activate therapies within tumors and reduce systemic toxicity while extending pre-activation half-life. These proposed advantages remain to be established in larger, later-stage clinical trials.
• Merck selected both collaboration targets. Janux may receive development and regulatory milestones, commercial milestones and royalties, but those contingent payments were excluded from the reported transaction price because achievement was uncertain. Merck controls development and commercialization after the research term and may terminate the agreement.

Liquidity, outlook and risks

• Management stated that year-end 2023 cash and investments were expected to fund operating expenses and capital requirements for at least 12 months after the filing. Janux also cautioned that its estimates depend on assumptions and that existing resources would not fund its candidates through regulatory approval; substantial additional capital will be needed.
• In March 2024, after year-end, Janux completed an underwritten offering of common stock and pre-funded warrants for $341.0 million gross proceeds and estimated $320.2 million net proceeds. This materially increased post-year-end liquidity and diluted existing holders. The filing’s runway statement is based on the stated operating plan and should be reassessed in light of this financing and subsequent spending.
• Janux expects R&D and G&A expenses and operating losses to increase as clinical and preclinical development proceeds. It provided no specific revenue, earnings, clinical milestone or profitability guidance.
• Principal risks include clinical failure or safety findings, uncertain translation of early data, regulatory delays, dependence on third-party CROs and a single-source bulk drug substance manufacturer, competition, intellectual-property challenges, and the need for future financing. The company also highlighted inflation, market volatility, data privacy and cybersecurity, and potential disruption to operations or suppliers.
• The company had no material legal proceedings. Its financial statements were audited by Ernst & Young LLP, which issued an unqualified opinion; the auditor did not attest to internal control over financial reporting because of the company’s emerging-growth-company exemption. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2023.

Important facts for investors to verify

• Updated JANX007 and JANX008 trial results, including cohort sizes, follow-up, durability, response criteria and complete safety data.
• Cash, investments, operating cash burn and runway after the March 2024 financing, including the impact of clinical-trial and manufacturing costs.
• Any changes to trial design, dose escalation, enrollment, regulatory plans or the timing of future data disclosures; the filing gives no specific schedule.
• Merck program progress and the conditions, timing and likelihood of any milestones or royalties; these are not assured revenue.
• Manufacturing supply continuity and the status of qualifying alternative suppliers, as bulk drug substance was sourced from a single third-party manufacturer.
• Potential dilution from outstanding pre-funded warrants, stock options and equity-plan reserves, alongside the March 2024 offering.